Predictors of Basal Cell Carcinoma and Implications for Follow-Up in High-Risk Patients in the Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial

J Cutan Med Surg. 2021 Jan-Feb;25(1):102-103. doi: 10.1177/1203475420945230. Epub 2020 Sep 3.

Authors

Meghan Beatson^{1

2

3}, Angelica Misitzis^{1

2}, Shoshana Landow^{1

2}, Jean Yoon⁴, H William Higgins 2nd², Ciaran Phibbs^{4

5}, Martin A Weinstock^{1

2}

Affiliations

¹ Center for Dermatoepidemiology-111D, Veterans Affairs Medical Center, Providence, RI, USA.
² Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, USA.
³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁴ Health Economics Resource Center and Center for Innovation to Implementation, Veterans Affairs Palo Alto, USA.
⁵ Stanford University School of Medicine, Palo Alto, CA, USA.

PMID: 32880186
DOI: 10.1177/1203475420945230

No abstract available

Keywords: 5-fluorouracil; BCC; chemoprevention; follow-up; predictors; risk.

Publication types

Letter

MeSH terms

Carcinoma, Basal Cell / diagnosis*
Carcinoma, Basal Cell / prevention & control*
Delayed Diagnosis / economics*
Female
Health Care Costs*
Humans
Keratinocytes
Male
Risk Assessment
Skin Neoplasms / diagnosis*
Skin Neoplasms / prevention & control*
United States
Veterans